Litcius/Paper detail

Upregulation of PD-L1 in Senescence and Aging

Angelique Onorati, Aaron Havas, Brian Lin, Jayaraj Rajagopal, Payel Sen, Peter D. Adams, Zhixun Dou

2022Molecular and Cellular Biology123 citationsDOIOpen Access PDF

Abstract

Cellular senescence is a stable form of cell cycle arrest associated with proinflammatory responses. Senescent cells can be cleared by the immune system as a part of normal tissue homeostasis. However, senescent cells can also accumulate in aged and diseased tissues, contributing to inflammation and disease progression. The mechanisms mediating the impaired immune-mediated clearance of senescent cells are poorly understood. Here, we report that senescent cells upregulate the immune checkpoint molecule PD-L1, the ligand for PD-1 on immune cells, which drives immune cell inactivation. The induction of PD-L1 in senescence is dependent on the proinflammatory program. Furthermore, the secreted factors released by senescent cells are sufficient to upregulate PD-L1 in nonsenescent control cells, mediated by the JAK-STAT pathway. In addition, we show that prolongevity intervention rapamycin downregulates PD-L1 in senescent cells. Last, we found that PD-L1 is upregulated in several tissues in naturally aged mice and in the lungs of idiopathic pulmonary fibrosis patients. Together, our results report that senescence and aging are associated with upregulation of a major immune checkpoint molecule, PD-L1. Targeting PD-L1 may offer new therapeutic opportunities in treating senescence and age-associated diseases.

Topics & Concepts

Downregulation and upregulationSenescenceProinflammatory cytokineImmune systemBiologyCell biologyInflammationImmunologyPD-L1Cancer researchImmunotherapyBiochemistryGeneNeutrophil, Myeloperoxidase and Oxidative MechanismsTelomeres, Telomerase, and SenescenceImmune cells in cancer
Upregulation of PD-L1 in Senescence and Aging | Litcius